The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis
Open accessAbstract
BACKGROUND The adjuvanted recombinant zoster vaccine (Shingrix) can prevent herpes zoster in older adults and autologous haemopoietic stem cell transplant recipients. We evaluated the safety and immunogenicity of this vaccine in adults with haematological malignancies receiving immunosuppressive cancer treatments. METHODS In this phase 3, randomised, observer-blind, placebo-controlled study, done at 77 centres worldwide, we randomly assigned (1:1) patients with haematological malignancies aged 18 years and older to receive two doses of the adjuvanted recombinant zoster vaccine or placebo 1-2 months apart during or after immunosuppressive cancer treatments, and stratified participants according to their underlying diseases. The co-primary objectives of the study were the evaluation of safety and reactogenicity of the adjuvanted recombinant zoster vaccine compared with placebo from the first vaccination up to 30 days after last vaccination in all participants; evaluation of the proportion of participants with a vaccine response in terms of anti-glycoprotein E humoral immune response to the adjuvanted recombinant zoster vaccine at month 2 in all participants, excluding those with non-Hodgkin B-cell lymphoma and chronic lymphocytic leukaemia; and evaluation of the anti-glycoprotein E humoral immune responses to the vaccine compared with placebo at month 2 in all participants, excluding those with non-Hodgkin B-cell lymphoma and chronic lymphocytic leukaemia. We assessed immunogenicity in the per-protocol cohort for immunogenicity and safety in the total vaccinated cohort. The study is registered with ClinicalTrials.gov, number NCT01767467, and with the EU Clinical Trials Register, number 2012-003438-18. FINDINGS Between March 1, 2013, and Sept 10, 2015, we randomly assigned 286 participants to adjuvanted recombinant zoster vaccine and 283 to placebo. 283 in the vaccine group and 279 in the placebo group were vaccinated. At month 2, 119 (80·4%, 95% CI 73·1-86·5) of 148 participants had a humoral vaccine response to adjuvanted recombinant zoster vaccine, compared with one (0·8%, 0·0-4·2) of 130 participants in the placebo group, and the adjusted geometric mean anti-glycoprotein E antibody concentration was 23 132·9 mIU/mL (95% CI 16 642·8-32 153·9) in the vaccine group and 777·6 mIU/mL (702·8-860·3) in the placebo group (adjusted geometric mean ratio 29·75, 21·09-41·96; p<0·0001) in all patients, excluding those with non-Hodgkin B-cell lymphoma and chronic lymphocytic leukaemia. Humoral and cell-mediated immune responses persisted above baseline until month 13 in all strata and, as expected, vaccine was more reactogenic than placebo (within 7 days after vaccination pain was reported by 221 [79·5%] of 278 vaccine group participants and 45 [16·4%] of 274 placebo group participants; fatigue was reported by 162 [58·3%] of 278 vaccine group participants and 102 [37·2%] of 274 placebo group participants). Incidences of unsolicited or serious adverse events, potential immune-mediated diseases, disease-related events, and fatal serious adverse events were similar between the groups. INTERPRETATION The immunocompromised adult population with haematological malignancies is at high risk for herpes zoster. The adjuvanted recombinant zoster vaccine, which is currently licensed in certain countries for adults aged 50 years and older, is likely to benefit this population. FUNDING GlaxoSmithKline Biologicals SA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Self-citationArmitage, J. O., Gascoyne, R. D., Lunning, M. A., & Cavalli, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32407-2 · Cited by 1,176
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603800 · Cited by 1,070
Self-citationRecommendations for the management of herpes zoster
Dworkin, R. H., Johnson, R. W., Breuer, J., Gnann, J. W., Levin, M. J., Backonja, M., Betts, R. F., Gershon, A. A., Haanpää, M. L., McKendrick, M. W., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/510206 · Cited by 869
Shankland, K. R., Armitage, J. O., & Hancock, B. W. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60605-9 · Cited by 641
The incidence of herpes zoster in a United States administrative database
Insinga, R. P., Itzler, R. F., Pellissier, J. M., Saddier, P., & Nikas, A. A. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0150.x · Cited by 490
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
Nucci, M., & Anaissie, E. (2009) · Clinical Infectious Diseases · doi:10.1086/605664 · Cited by 347
The global epidemiology of herpes zoster
Yawn, B. P., & Gilden, D. (2013) · Neurology · doi:10.1212/wnl.0b013e3182a3516e · Cited by 347
Use of an Inactivated Varicella Vaccine in Recipients of Hematopoietic-Cell Transplants
Hata, A., Asanuma, H., Rinki, M., Sharp, M., Wong, R. M., Blume, K., & Arvin, A. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013441 · Cited by 300
Infections in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine
Anaissie, E. J., Kontoyiannis, D. P., O'Brien, S., Kantarjian, H., Robertson, L., Lerner, S., & Keating, M. J. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-7-199810010-00010 · Cited by 297
Cited by
Anderson, T. C., Masters, N. B., Guo, A., Shepersky, L., Leidner, A. J., Lee, G. M., Kotton, C. N., & Dooling, K. L. (2022) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7103a2 · Cited by 261
Zhang, M., Liu, C., Tu, J., Tang, M., Ashrafizadeh, M., Nabavi, N., Sethi, G., Zhao, P., & Liu, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02305-x · Cited by 259
Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00283-0 · Cited by 212
Laws, H.-J., Baumann, U., Bogdan, C., Burchard, G., Christopeit, M., Hecht, J., Heininger, U., Hilgendorf, I., Kern, W., Kling, K., et al. (2020) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-020-03123-w · Cited by 88
Mhibik, M., Gaglione, E. M., Eik, D., Kendall, E. K., Blackburn, A., Keyvanfar, K., Baptista, M. J., Ahn, I. E., Sun, C., Qi, J., et al. (2021) · Blood · doi:10.1182/blood.2020009686 · Cited by 30
Metadata
- Authors
- Dagnew, A. F., Ilhan, O., Lee, W.-S., Woszczyk, D., Kwak, J.-Y., Bowcock, S., Sohn, S. K., Rodriguez Macías, G., Chiou, T.-J., Quiel, D., Aoun, M., Navarro Matilla, M. B., de la Serna, J., Milliken, S., Murphy, J., McNeil, S. A., Salaun, B., Di Paolo, E., Campora, L., López-Fauqued, M., El Idrissi, M., Schuind, A., Heineman, T. C., Van den Steen, P., Oostvogels, L., Acar, K., Afanasyev, B., Alonso Alonso, A., Anttila, V.-J., Barba Suñol, P., Blesing, N., Comeau, T., del Campo, T., Disperati, P., Eek, R., Eom, H., Gaidano, G., Grosicki, S., Guillaume, T., Homenda, W., Hwang, W., Ilyin, N., Johnston, A., Kim, S. J., Kuo, C.-Y., Kuvshinov, A., Lee, D.-G., Lee, J. H., Lee, J.-J., Lepretre, S., Lie, A. K.-W., Lucchesi, A., Masood, A., Mir, N., Miranda Castillo, A. C., Mullane, K., Myasnikov, A., Oña Navarrete, R., Pauksens, K., Peniket, A., Perez de Oteyza, J., Pohlreich, D., Pullon, H., Quittet, P., Rodon, P., Rombo, L., Samoylova, O., Sanmartin Berglund, J., Schattner, A., Selleslag, D., Sinisalo, M., Sultan, F., Theunissen, K., Turner, P., Wang, P.-N., Yáñez San Segundo, L., Young, J.-A., Zachee, P., & Zaja, F.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 19
- Issue
- 9
- Pages
- 988-1000
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W2965743944
- Cited by
- 255
- References
- 32
- FWCI
- 17.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. https://app.cochat.ai/papers/10.1016/s1473-3099(19)30163-x
- The paper
- Dagnew, A. F., Ilhan, O., Lee, W.-S., Woszczyk, D., Kwak, J.-Y., Bowcock, S., Sohn, S. K., Rodriguez Macías, G., Chiou, T.-J., Quiel, D., Aoun, M., Navarro Matilla, M. B., de la Serna, J., Milliken, S., Murphy, J., McNeil, S. A., Salaun, B., Di Paolo, E., Campora, L., . . . Zaja, F. (2019). Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(19)30163-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.